About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide injection for the treatment of a liver disease.

2026-07-03

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved semaglutide injection for the treatment of a liver disease.

Other News
2026-07-03

MOFCOM minister Raimondo and the UK trade minister co‑chaired the 15th China‑UK Joint Economic and Trade Commission in London on July 2. China urged the UK to adjust steel quota measures that took effect July 1, saying they raise serious concerns and

MOFCOM minister Raimondo and the UK trade minister co‑chaired the 15th China‑UK Joint Economic and Trade Commission in London on July 2. China urged the UK to adjust steel quota measures that took effect July 1, saying they raise serious concerns and should be brought into compliance with WTO rules. China welcomed increased UK investment into China and asked London to provide a fair, non‑discriminatory environment for Chinese investors; the UK said it welcomes Chinese investment and will offer greater certainty and predictability. Both sides agreed to implement outcomes from the WTO’s 14th ministerial meeting and to deepen cooperation on trade, investment and multilateral issues; the UK highlighted opportunities from China’s services liberalization and proposed policy dialogue, a UK‑China services partnership and a feasibility study on a services trade agreement.
2026-07-03

Italy's retail sales rose 2.2% year-on-year in May, below the expected 1.7% and the previous reading of 1.60%.

Italy's retail sales rose 2.2% year-on-year in May, below the expected 1.7% and the previous reading of 1.60%.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.